35 results about "DIAGNOSTIC STANDARD" patented technology

The invention discloses application of a biomarker for preparing a medicine for predicting feedback response of 5-aminosalicylic acid in treatment of ulcerative colitis. The biomarker determined in the invention is the basis of a target biomarker associated with gender difference response when 5-aminosalicylic acid (5-ASA) is used to treat ulcerative colitis (UC). The biomarker comprises a group of protein biomarkers which can differentiate response difference for treatment by 5-ASA between different genders and determine the curative effect by using 5-ASA under different UC conditions. Meanwhile, a novel drug target for a UC novel curative method is effectively determined and verified by using the biomarker with specificity for genders and disease focus parts, novel diagnostic reagents, medicines, methods and diagnostic standards are developed, and the application is used for establishing a UC treatment policy.

A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified target biomarkers associated with gender differential responses to mesalamine, and includes one or more panels of target biomarkers that distinguishes mesalamine response differences between genders and determines the efficacy of mesalamine for patients being treated for various UC conditions and effectively identifies and validates novel drug targets for new UC therapeutics, new diagnostics and diagnostics standards for UC therapeutic strategies.

The invention discloses application of CD4+T lymphocyte characteristic protein to identification of active tuberculosis and latent tuberculosis infection (LTBI). The invention provides application ofa substance for detecting an expression quantity of integrin beta-3 and / or integrin-linked kinase to preparation of a product for distinguishing or identifying or assisting to distinguish or identifya patient with the active tuberculosis and a latent tuberculosis infection infected person. The invention finds out that integrin beta-3 and integrin-linked kinase protein can distinguish an LTBI patient and an initially-treated active tuberculosis patient, and novel diagnostic standards are provided for diagnosing the LTBI patient and the initially-treated active tuberculosis patient.

An embodiment of the present application provides a vehicle diagnosis method, a diagnosis terminal and a diagnosis box, wherein a vehicle diagnosis method includes: the diagnosis terminal determines the diagnosis category of the vehicle to be diagnosed according to the received diagnosis instruction; further, according to the diagnosis category Determine the target diagnostic mode of the diagnostic box required for diagnosing the vehicle to be diagnosed; the diagnostic terminal obtains the current diagnostic mode of the diagnostic box; if the two diagnostic modes are different, the diagnostic terminal sends a diagnostic mode switching command to the diagnostic box To prompt the diagnostic box to switch to the target diagnostic mode, so that the diagnostic terminal can diagnose the vehicle to be diagnosed through the diagnostic box working in the target diagnostic mode. By adopting the embodiment of the present application, by integrating the diagnostic box and the diagnostic software that support the diagnostic standards of the new model and the old model, the automatic selection of the appropriate diagnostic mode according to the model to be diagnosed is realized, and the frequent switching of the diagnosis of the diagnostic box is avoided. Mode and diagnostic software, improving diagnostic efficiency.

The invention discloses a configurable method for a diagnostic protocol stack based on a CAN (controller area network) bus. The diagnostic protocol stack is realized according to international diagnostic standards ISO (international standardization organization) 15765 and AUTOSAR (automotive open system architecture) standards, and comprises an encapsulated network layer, an application layer module, an application layer standard interface, an ECU (electronic control unit) abstraction layer standard interface and a configurable file. When users carry out diagnostic requirement development, the existing module is applied for setting the configurable parameters through the configurable file, and only the concentration on the realization of application layer and bottom layer driving according to the standard interface is needed. The configurable method has the advantages that the universality, the reliability and the portability of diagnostic software are enhanced, the transplantation on different hardware platforms is convenient, the repeated development of the protocol stack of the network layer and an application layer is avoided, the development time is greatly shortened, the development cost is reduced, and the development and the expansion are convenient.

A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified target biomarkers associated with gender differential responses to mesalamine, and includes one or more panels of target biomarkers that distinguishes mesalamine response differences between genders and determines the efficacy of mesalamine for patients being treated for various UC conditions and effectively identifies and validates novel drug targets for new UC therapeutics, new diagnostics and diagnostics standards for UC therapeutic strategies.

A Helicobacter pylori staining solution and a staining method thereof, the staining solution is composed of the following raw materials: 6-18mg / mL methylene blue, 3-9mg / mL sodium borate, and the rest is distilled water, with the mass-volume ratio mg / mL as the unit. In the present invention, the sample tissue section is immersed in the above-mentioned Helicobacter pylori staining solution and dyed for <10s; the stained sample section is washed with running water, and then soaked in 95% ethanol, absolute ethanol, n-butanol, xylene, dehydrated, and dehydrated Afterwards, it was wet-sealed with neutral gum to obtain the stained slide sample; HP in the stained slide sample was observed under a microscope, and the diagnosis and interpretation of HP was performed according to the "China Chronic Gastritis Consensus (2017, Shanghai)". The present invention replaces boric acid with sodium borate to prepare methylene blue dye solution for staining Helicobacter pylori, significantly shortens the dyeing time, has the advantages of saving time and labor, deep bacterial color, easy microscopic examination and the like, and meets the diagnostic standard.